---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-055078"
form_type: "8-K/A"
ticker: "LIMN"
cik: "0001971387"
company_name: "Liminatus Pharma, Inc."
filed_at: "2025-06-02T23:59:59+00:00"
generated_at: "2026-05-20T03:22:01.366053+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "medium"
source: SEC EDGAR
---

# Liminatus Pharma completes de-SPAC business combination, files Q1 2025 financials

## Summary
- Business combination closed April 30, 2025; combined company trades on Nasdaq as LIMN and LIMNW.
- Public stockholders redeemed 59,844 shares for ~$702k (~$11.74/share).
- Liminatus is pre-revenue, pre-clinical; net loss of $3.5M in FY2024, $5.0M in FY2023, accumulated deficit $28.7M.
- Amendment adds unaudited Q1 2025 financial statements of Liminatus and Iris; specific results not summarized in filing.
- Enterprise value of Liminatus set at $175M; 17,500,000 common shares issued to former Liminatus securityholders.

## SEC filing metadata
- accession: 0001104659-25-055078
- form_type: 8-K/A
- ticker: LIMN
- cik: 0001971387
- company_name: Liminatus Pharma, Inc.
- filed_at: 2025-06-02T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: medium
- sec_items: 2.01, 9.01, 1.01, 5.02, 3.02, 4.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1971387/000110465925055078/0001104659-25-055078-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1971387/000110465925055078/tm2516317d1_8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-055078
- JSON: https://secwatch.observer/filing/0001104659-25-055078.json
- Plain text: https://secwatch.observer/filing/0001104659-25-055078.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.